Skip Navigation


NDT Advance Access originally published online on October 16, 2008
Nephrology Dialysis Transplantation 2009 24(2):630-638; doi:10.1093/ndt/gfn574
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
24/2/630    most recent
gfn574v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Letavernier, E.
Right arrow Articles by Baud, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Letavernier, E.
Right arrow Articles by Baud, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


Sirolimus interacts with pathways essential for podocyte integrity

Emmanuel Letavernier1, Patrick Bruneval2, Sophie Vandermeersch1, Joelle Perez1, Chantal Mandet2, Marie-France Belair2, Jean-philippe Haymann1, Christophe Legendre3 and Laurent Baud1

1 INSERM, U702 and Université Pierre et Marie Curie-Paris 6, UMRS702 2 INSERM, UMRS872, Centre de Recherches des Cordeliers and Université Paris Descartes 3 Service de Transplantation Adulte, Hôpital Necker, Paris, France

Correspondence and offprint requests to: Emmanuel Letavernier, INSERM U702, Hôpital Tenon, 4 rue de la Chine, 75020 Paris, France. Tel: +33-1-56-01-79-51; Fax: +33-1-56-01-70-03; E-mail: emmanuel.letavernier{at}tnn.ap-hop-paris.fr



  Abstract

Background. The specific mTor inhibitor sirolimus has been implicated in the pathogenesis of renal glomerular lesions and nephrotic syndrome appearance after transplantation. Podocyte injury and focal segmental glomerulosclerosis have been related to sirolimus therapy in some patients but the pathways underlying these lesions remain hypothetical.

Methods. To go further in the comprehension of these mechanisms, primary cultures of human podocytes were exposed to therapeutic-range concentrations of sirolimus.

Results. Cell viability was not affected after 2 days’ exposure to the drug but changes in cell phenotype and cytoskeleton reorganization were observed. We also evidenced that vascular endothelial growth factor (VEGF) synthesis and Akt phosphorylation were decreased by sirolimus addition. We did not observe any loss of podocyte differentiation markers with the notable exception of WT1, a transcription factor essential for maintaining podocyte integrity. WT1 gene and protein expression in podocytes were decreased in a dose-dependent manner after incubation with sirolimus.

Conclusion. Taken together, these data suggest that sirolimus could impair pathways essential for podocyte integrity and therefore predisposes to glomerular injury.

Keywords: podocyte; sirolimus; toxicity; VEGF; WT1

Received for publication: 16. 2.08
Accepted in revised form: 19. 9.08


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Pathol.Home page
R John and A M Herzenberg
Renal toxicity of therapeutic drugs
J. Clin. Pathol., June 1, 2009; 62(6): 505 - 515.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.